Italian Titration Approach Study (ITAS) with insulin glargine 300 U/mL in insulin-naive type 2 diabetes: Design and population

被引:11
|
作者
Bonadonna, R. C. [1 ]
Giaccari, A. [2 ,3 ]
Buzzetti, R. [4 ]
Aimaretti, G. [5 ]
Cucinotta, D. [6 ]
Avogaro, A. [7 ]
Perseghin, G. [8 ]
Larosa, M. [9 ]
Bolli, G. B. [10 ]
Fanelli, C. G. [10 ]
机构
[1] Univ Parma, Div Endocrinol & Metab Dis, Dept Med & Surg, AOU Parma, Via Gramsci 14, I-43126 Parma, Italy
[2] Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy
[3] Univ Cattolica Sacro Cuore, Rome, Italy
[4] Sapienza Univ Rome, Rome, RM, Italy
[5] Univ Eastern Piedmt, Vercelli, VC, Italy
[6] Univ Messina, Messina, Italy
[7] Univ Padua, Padua, Italy
[8] Univ Milano Bicocca, Milan, MI, Italy
[9] Sanofi, Milan, Italy
[10] Perugia Univ, Sect Endocrinol & Metab, Dept Med, Med Sch, Perugia, Italy
关键词
Type; 2; diabetes; Insulin glargine 300 U/mL; Patient empowerment; Insulin titration; GLYCEMIC CONTROL; CLINICAL INERTIA; PEOPLE; INTENSIFICATION; HYPOGLYCEMIA; INITIATION; BARRIERS;
D O I
10.1016/j.numecd.2019.01.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and aims: Fostering patient's self-managing of basal insulin therapy could improve glucose control, by removing patient's and physician's barriers to basal insulin initiation, titration and glucose monitoring. The Italian Titration Approaches Study (ITAS) aims at demonstrating non-inferiority (<0.3% margin) in efficacy of glucose control (change in glycated hemoglobin [HbA1c] after 24 weeks) by the same titration algorithm of insulin glargine 300 U/mL (Gla-300), managed by the (nurse assisted) patient versus the physician, in insulin naive patients with Type 2 Diabetes Mellitus (T2DM), uncontrolled with previous treatments. Methods and results: ITAS is a phase IV, 24-week, national, multicenter, open label, randomized (1:1) parallel group study. 458 patients were enrolled, 359 randomized, and 339 completed the study, in 46 Italian centers. Baseline characteristics and previous medications of the ITT population (N = 355) are reported. Mean +/- SD age, T2DM duration, HbA1c, FPG and BMI were 64.0 +/- 9.8 years, 11.6 +/- 7.6 years, 8.79 +/- 0.65%, 170.9 +/- 42.3 mg/dL, and 30.3 +/- 5.6 kg/m(2) , respectively. Vascular and metabolic disorders were most frequent (73.8% and 58.3%, respectively). More than 90% of patients were on metformin. Conclusion: ITAS is the first study to compare two different managers (nurse-assisted patient vs physician) of the same titration algorithm of Gla-300 in insulin naive patients with T2DM in unsatisfactory glucose control. This study might provide novel evidence on the efficacy/ Acronyms: effectiveness of patient-managed titration algorithm of Gla-300 in a pragmatic setting and may reduce barriers to basal insulin initiation and its titration. (C) 2019 Published by Elsevier B.V. on behalf of The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University.
引用
收藏
页码:496 / 503
页数:8
相关论文
共 50 条
  • [1] Italian Titration Approach Study (ITAS) with insulin glargine 300 U/mL in insulin-naive type 2 diabetes: Design and population (vol 29, pg 496, 2019)
    Bonadonna, R. C.
    Giaccari, A.
    Buzzetti, R.
    Aimaretti, G.
    Cucinotta, D.
    Avogaro, A.
    Perseghin, G.
    Larosa, M.
    Bolli, G. B.
    Fanelli, C. G.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2019, 29 (08) : 869 - 870
  • [2] A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin-naive patients with type 2 diabetes
    Tibaldi, Joseph
    Hadley-Brown, Martin
    Liebl, Andreas
    Haldrup, Steffen
    Sandberg, Viktor
    Wolden, Michael L.
    Rodbard, Helena W.
    DIABETES OBESITY & METABOLISM, 2019, 21 (04): : 1001 - 1009
  • [3] TITRATION PATTERNS OF INSULIN GLARGINE 300 U/ML IN INSULIN-NAIVE PEOPLE WITH TYPE 2 DIABETES AND CLINICAL OUTCOMES: A SUBGROUP ANALYSIS OF ATOS STUDY
    Tirosh, A.
    Singh, A. K.
    Vargas-Uricoechea, H.
    Mabunay, M. A.
    Bigot, G.
    Naqvi, M.
    Galstyan, G.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 : A132 - A133
  • [4] Titration patterns of insulin glargine 300 U/mL in insulin-naive people with type 2 diabetes and clinical outcomes: a subgroup analysis of ATOS study
    Tirosh, A.
    Singh, A.
    Vargas-Uricoechea, H.
    Mabunay, M. A.
    Bigot, G.
    Naqvi, M.
    Galstyan, G.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S355 - S355
  • [5] CONFIRM: a comparative effectiveness study of insulin degludec and insulin glargine 300 units/ ml (glargine U300) in insulin-naive patients with type 2 diabetes
    Tibaldi, J.
    Haldrup, S.
    Sandberg, V.
    Wolden, M. L.
    Rodbard, H. W.
    DIABETOLOGIA, 2018, 61 : S44 - S44
  • [6] Comment on "a comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin-naive patients with type 2 diabetes"
    Freemantle, Nick
    Jourdan, Sophie
    DIABETES OBESITY & METABOLISM, 2019, 21 (07): : 1758 - 1759
  • [7] EASE OF USE OF THE NEW INSULIN GLARGINE 300 U/ML PEN INJECTOR IN INSULIN-NAIVE PEOPLE WITH TYPE 2 DIABETES
    Pohlmeier, H.
    Klonoff, D.
    Berard, L.
    Brulle-Wohlhueter, C.
    Wu, J.
    Dahmen, R.
    Nowotny, I.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 : A18 - A19
  • [8] Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naive People with Type 2 Diabetes: the ATOS Study
    Galstyan, Gagik R.
    Tirosh, Amir
    Vargas-Uricoechea, Hernando
    Mabunay, Maria Aileen
    Coudert, Mathieu
    Naqvi, Mubarak
    Pilorget, Valerie
    Khan, Niaz
    DIABETES THERAPY, 2022, 13 (06) : 1187 - 1202
  • [9] Ease of Use of the New Insulin Glargine 300 U/mL SoloSTAR Pen Injector in Insulin-Naive People with Type 2 Diabetes
    Pohlmeier, Harald
    Klonoff, David C.
    Berard, Lori
    Brulle-Wohlhueter, Claire
    Wu, Junlong
    Dahmen, Raphael
    Nowotny, Irene
    DIABETES, 2015, 64 : A269 - A270
  • [10] Lower hypoglycaemia rates with insulin glargine 300 U/ml vs insulin degludec 100 U/ml in insulin-naive adults with type 2 diabetes: the BRIGHT randomised trial
    Bolli, G. B.
    Cheng, A.
    Bosnyak, Z.
    Boelle-Le Corfec, E.
    Cali, A. M. G.
    Wang, X.
    Frias, J.
    Roussel, R.
    Rosenstock, J.
    DIABETOLOGIA, 2018, 61 : S442 - S442